Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045

J. Bellmunt, R. de Wit, D. J. Vaughn, Y. Fradet, J. L. Lee, L. Fong, N. J. Vogelzang, M. A. Climent, D. Petrylak, T. K. Choueiri, A. Necchi, W. R. Gerritsen, H. Gurney, D. I. Quinn, S. Culine, C. N. Sternberg, E. Jensen, T. Frenkl, R. F. Perini, D. Bajorin

Research output: Contribution to journalMeeting abstractpeer-review

7 Downloads (Pure)
Original languageEnglish
Pages (from-to)viii320-viii321
Number of pages2
JournalAnnals of Oncology
Issue numberSupplement 8
Publication statusPublished - 1 Oct 2018
Event43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany
Duration: 19 Oct 201823 Oct 2018

Bibliographical note

Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this